NDA 212819 · Msd Merck CO
Recarbrio
Cilastatin Sodium, Imipenem, Relebactam · Intravenous · Penem Antibacterial; Renal Dehydropeptidase Inhibitor; beta Lactamase Inhibitor
NovelPriority reviewDiscontinuedLast checked: Nov 19, 2026Latest source record: Dec 9, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Jul 16, 2019
Approved uses
3
Original approval plus efficacy supplements
Registered trials
65
21 Phase 3, 2 recruiting
FAERS reports
92
75 serious, 25 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 9, 2025.
RECARBRIO is a combination of imipenem, a penem antibacterial, cilastatin, a renal dehydropeptidase inhibitor, and relebactam, a beta-lactamase inhibitor, indicated in adult and pediatric patients weighing at least 2 kg for the treatment of the following infections caused by susceptible gram-negative microorganisms: Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP). ( 1.1 ) Complicated urinary tract infections, including pyelonephritis (cUTI) in patients who have limited or no alternative treatment options. ( 1.2 ) Complicated intra-abdominal infections (cIAI) in patients who have limited or no alternative treatment options. ( 1.3 ) Approval of the cUTI and cIAI indications is based on limited clinical safety and efficacy data for RECARBRIO. ( 1.2 , 1.3 , 14 ) Limitations of Use RECARBRIO is not recommended in pediatric patients less than 37 weeks post-menstrual age (gestational age at birth plus post-natal age). ( 1.4 , 2.2 ). RECARBRIO is not recommended in pediatric patients weighing less than 30 kg with renal impairment. ( 1.4 , 2.3 ). Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug-resistant bacteria and maintain the effectiveness of RECARBRIO and other antibacterial drugs, RECARBRIO should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.5 ) 1.1 Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP) RECARBRIO ® is indicated in adult and pediatric patients weighing at least 2 kg for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, caused by the following susceptible gram-negative microorganisms: Acinetobacter...
Mechanism: RECARBRIO is an antibacterial drug [see Microbiology (12.4) ].
Therapeutic areas: Cardiovascular and metabolic · Infectious disease and vaccines · Kidney and urology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 9, 2025 Supplement 8 · Efficacy LetterLabel
- Jun 4, 2020 Supplement 2 · Efficacy · priority review LabelLetter
- Jul 16, 2019 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination · priority review NovelLabelLetterReview
1 products under this application
- RECARBRIO · CILASTATIN SODIUM EQ 500MG BASE/VIAL; IMIPENEM 500MG/VIAL; RELEBACTAM 250MG/VIAL · POWDER, INTRAVENOUS · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Cilastatin" as an intervention, any sponsor and status, largest first.
- A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)Pivotal-lookingCompleted
Spero TherapeuticsIndustry
NCT06059846 · 1,690 participants · Start Dec 21, 2023 · Primary completion Jan 27, 2025
Drug: TBP-PI-HBr; Imipenem-cilastatin and 2 more · For: Urinary Tract Infection; Acute Pyelonephritis
Sites: Miami, Florida; Buenos Aires, Argentina; Córdoba, Argentina · 85 sites in all
- Complicated Skin and Skin Structure InfectionsPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00619710 · 1,000 participants (planned) · Start Feb 2001 · Primary completion Dec 2003
Drug: Meropenem; Imipenem-cilastatin · For: Skin Infection; Abscess; Cellulitis
- Study Comparing Tigecycline to Imipenem/Cilastatin in Complicated Intra-Abdominal Infections in Hospitalized SubjectsPivotal-lookingCompleted
Wyeth is now a wholly owned subsidiary of PfizerPfizer (PFE)
NCT00081744 · 850 participants · Start Nov 2002 · Primary completion Aug 2004
Drug: Tigecycline · For: Gram-Positive Bacterial Infections; Cross Infection
- Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With cUTI Including AP (EudraCT no. 2022-000061-40)Pivotal-lookingStatus unknown
Evopoint Biosciences Inc.Industry
NCT05204368 · 780 participants (planned) · Start Mar 30, 2023 · Primary completion Jun 2025
Drug: Combination of Imipenem/Cilastatin and XNW4107; Meropenem · For: Complicated Urinary Tract Infection Including Acute Pyelonephritis
Sites: Baltimore, Maryland
- Prevention of Nephrotoxin-Induced Acute Kidney Injury Using CilastatinPivotal-lookingRecruiting
Matthew JamesAcademic, hospital or other
NCT06886464 · 698 participants (planned) · Start Jul 16, 2025 · Primary completion Dec 31, 2027
Drug: Cilastatin Sodium; Placebo-Saline · For: Acute Kidney Injury
Sites: Calgary, Canada; Edmonton, Canada
- Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated PyelonephritisPivotal-lookingCompleted
Meiji Seika Pharma Co., Ltd.Industry
NCT05887908 · 614 participants · Start May 23, 2023 · Primary completion Nov 22, 2024
Drug: co-administration of cefepime and nacubactam; co-administration of aztreonam and nacubactam and 1 more · For: Complicated Urinary Tract Infection; Acute Pyelonephritis; cUTI and 1 more
Sites: Pleven, Bulgaria; Rousse, Bulgaria; Silistra, Bulgaria · 61 sites in all
- A Trial of HRS-8427 in the Treatment of Adults With Complicated Urinary Tract Infection, Including Acute PyelonephritisPivotal-lookingCompleted
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT06569056 · 579 participants · Start Sep 25, 2024 · Primary completion Sep 1, 2026
Drug: HRS-8427; Imipenem and Cilastatin Sodium and 2 more · For: Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)
Sites: Shanghai, China
- Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02493764 · 537 participants · Start Nov 24, 2015 · Primary completion Apr 3, 2019
Drug: Imipenem; Relebactam and 4 more · For: Bacterial Pneumonia
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use18
- death14
- product use in unapproved indication9
- pathogen resistance8
- drug ineffective6
- cardio-respiratory arrest5
- generalised tonic-clonic seizure5
- overdose5
- epilepsy4
- renal impairment4
- therapy non-responder4
- condition aggravated3
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2019 | 2 |
| 2021 | 16 |
| 2022 | 19 |
| 2023 | 21 |
| 2024 | 17 |
| 2025 | 12 |
| 2026 | 5 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
To Be Discontinued · updated Sep 9, 2026
RECARBRIO, Injection, 500 mg/100 mL; 500 mg/100 mL; 250 mg/100 mL (NDC 0006-3856-02). To be discontinued on or near late September 2026.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Recarbrio (Imipenem/Cilastatin/Relebactam)
2024 spending
$1.2M
Beneficiaries
32
178 claims
Per beneficiary
$38,331
$163.65 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $180,002 |
| 2021 | $941,895 |
| 2022 | $1,125,796 |
| 2023 | $1,052,578 |
| 2024 | $1,226,579 |
Part B: Recarbrio (Imipenem/Cilastatin/Relebactam) · HCPCS J0742
2024 spending
$2K
Beneficiaries
n/a
331 claims
Per beneficiary
n/a
2024 ASP limit $2.48 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $50,507 |
| 2021 | $35,886 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $1,916 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK).
Kaye KS, Shorr AF, Wunderink RG, et al. · Lancet Infect Dis 2023 · Randomized Controlled Trial, Multicenter Study
- The risk of seizures among the carbapenems: a meta-analysis.
Cannon JP, Lee TA, Clark NM, et al. · J Antimicrob Chemother 2014 · Meta-Analysis, Research Support, Non-U.S. Gov't
- A Systematic Review of the Pharmacokinetics and Pharmacodynamics of Novel Beta-Lactams and Beta-Lactam with Beta-Lactamase Inhibitor Combinations for the Treatment of Pneumonia Caused by Carbapenem-Resistant Gram-Negative Bacteria.
Rando E, Novy E, Sangiorgi F, et al. · Int J Antimicrob Agents 2024 · Systematic Review
- Efficacy, safety, and tolerability of antimicrobial agents for complicated intra-abdominal infection: a systematic review and network meta-analysis.
Kong W, Deng T, Li S, et al. · BMC Infect Dis 2023 · Systematic Review, Network Meta-Analysis
- Antibiotics for ventilator-associated pneumonia.
Arthur LE, Kizor RS, Selim AG, et al. · Cochrane Database Syst Rev 2016 · Meta-Analysis, Research Support, Non-U.S. Gov't
- A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study).
Titov I, Wunderink RG, Roquilly A, et al. · Clin Infect Dis 2021 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Merck & Co.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.